Clinical Trials Insight: 700053888
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2010
At a glance
- Drugs Clavulanic acid (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Rexahn Pharmaceuticals
- 06 Apr 2010 A phase II protocol for this trial has been submitted to the US Food and Drug Administration, according to a Rexahn Pharmaceuticals media release.
- 22 Feb 2010 New trial record
- 18 Feb 2010 The trial is expected to be initiated in the second quarter of 2010, as reported in a Rexahn Pharmaceuticals media release.